Clearside Biomedical Inc
NASDAQ:CLSD
| Market Cap (Intraday) | 347.51M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $5.61 |
| 50-Day MA | $6.11 |
| 200-Day MA | $4.24 |
Clearside Biomedical Inc Stock, NASDAQ:CLSD
900 North Point parkway, Suite 200, Alpharetta, Georgia 30005
United States of America
Phone: +1.678.270.3631
Number of Employees: 33
Description
Clearside Biomedical, Inc. is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.